Converge Bio
Trains generative models on DNA, RNA and protein sequences and sells them to drug developers as finished systems for antibody design and optimisation, protein manufacturing yield, and target and biomarker discovery. Customers can fine-tune private copies on their own data.
Money and evidence
No research by this company is on the record yet.
Rounds and research, on one timeline
- 2026-01-13Series ARound
$25M
For: not itemised; the release ties the round to its commercial traction and scientific results
Not stated
The company's release calls the round highly oversubscribed and says it brings the total raised to $30M; it also lists executives from Meta, OpenAI and Wiz, unnamed, as backers, and gives no valuation. Its dateline reads 13 January 2025, a slip for 2026: the newsroom and TechCrunch date it 13 January 2026.
Lead · Bessemer Venture Partners ✓TLV PartnersVintage Investment PartnersSaras Capital
On the deal: Andrew Hedin (Partner; spoke for the firm in the announcement, Bessemer Venture Partners)
Announced by the company · converge-bio.com ↗On the timeline →
- 2024-11-20SeedRound
$5.5M
For: hiring, winning customers, a scientific paper on antibody design and training a foundation model
HiringCommercial roll-outModels and platform
Read in TechCrunch's report, which the company's newsroom lists under its own headline 'Converge Bio Raises $5.5M in seed round led by TLV Partners'; the use of funds is TechCrunch's account of what the company told it.
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.
On the investors' own sites
Investors that name this company on their own site, in a portfolio or their own announcement. A ✓ in a round marks the same investor.
- Bessemer Venture Partnersbvp.com ↗
Its investors also backed
Other companies on this page whose rounds name the same investor.
- Saras CapitalUndecimal Bio